Murray and Tencent have jointly developed AI products for blood cell analysis

Pharma.com February 4 - Murray and Tencent jointly develop products Recently, according to Meirui Medical Official Micro-News, Meirui Medical and Tencent AI Lab signed an AI cooperation framework agreement to jointly develop AI products for blood cell analysis, and further explore the integration and application of AI technology in in-body diagnostics.
will rely on Tencent's Forage Open Lab to accelerate the construction of a new generation of artificial intelligence open innovation platform for the Ministry of Science and Technology's medical imaging country.
, according to the introduction, in blood cell analysis, that is, blood routine testing, automated blood cell analyzers mainly provide counting and classification results, reflecting changes in the number of outer blood cells, while morphological testing mainly reflects changes in the quality of blood cells.
, there are problems such as lack of talents and shortage of man-made personnel in morphological examination.
, a number of companies at home and abroad, out of a number of automated morphological analysis equipment.
these devices have the problem of low accuracy, the test still needs to invest a lot of manpower, does not fundamentally solve the clinical pain point.
This partnership between Murray Healthcare and Tencent AI Lab will leverage cutting-edge algorithms and related solutions such as machine learning and computer vision to advance myer's cell recognition capabilities to world-leading levels in the areas of slide processing, imaging systems, integrated design, clinical experts, and mass data.
In addition to morphological testing, the future Murray and Tencent AI Lab will explore the convergence and application of artificial intelligence technology in other areas of in-body diagnostics, such as urine analysis, intelligent laboratories, in-body diagnostic big data, and more.
This sub-area, the highest degree of domestic substitution is understood, for the significance of many disease diagnosis, changes in blood cell quality is more important than quantitative changes, it is for hematoplasty and lymphatic tissue tumors, anemia, infectious diseases, hemorrhagic diseases and other related diseases diagnosis, classification, phased guidance, and monitoring efficacy and prognosis to provide a direct and objective basis for testing and diagnosis.
because blood routines are the first screening tool for patient visits, it is important to achieve early screening-assisted clinical diagnosis through morphological testing, especially leukemia screening.
in blood cell analysis, morphological analysis reflects changes in blood cell quality and is of great clinical value for screening for blood diseases, especially malignant blood diseases such as leukemia.
according to the Annual Report of China's In-body Diagnostics Industry (2019), the blood body fluid testing market mainly includes clotting testing, blood cell analysis, urine analysis, urine physical analysis, etc.
market accounts for about 10% of the in-body diagnostics market, maintaining 10% growth.
, foreign-funded enterprises in China's blood coagulation market has an absolute advantage, is expected to occupy more than 80% of the market share.
blood cell counting products consist of blood cell analyzers, reagents, calibrations and quality control products.
blood cell analyzer is one of the most widely used instruments in clinical examination in hospitals, with the rapid development of computer technology in recent years, blood cell analysis technology has also changed from a three-part group to a five-point group.
As the key implementation of the sinking of medical and health resources, five-classification blood cell analyzer is gradually popularized in primary medical institutions, but the clinical examination laboratory of primary medical institutions is small in area, instrument, space is limited, so miniaturization will be the development direction of five-classification blood cell analyzer.
blood analyzer product market is the entire China IVD industry market China's product brand replacement of the most successful segment, relatively mature, domestic accounted for more than 50%.
three classification instruments are mainly domestic, imported products concentrated in the five categories.